ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended June 30, 2014 – the fourth quarter of the Company’s 2014 fiscal year. ImmunoGen also provided an update on product programs and guidance for its 2015 fiscal year.
Help employers find you! Check out all the jobs and post your resume.
